Norcuron

국가: 뉴질랜드

언어: 영어

출처: Medsafe (Medicines Safety Authority)

유효 성분:

Vecuronium bromide 10mg

제공처:

Merck Sharp & Dohme (New Zealand) Limited

INN (국제 이름):

Vecuronium bromide 10 mg

복용량:

10 mg

약제 형태:

Powder for injection

구성:

Active: Vecuronium bromide 10mg Excipient: Citric acid monohydrate Dibasic sodium phosphate Mannitol

패키지 단위:

Vial, glass, 10 dose units

수업:

Prescription

처방전 유형:

Prescription

Manufactured by:

Aspen Oss B.V

치료 징후:

NORCURON is indicated as an adjunct to general anaesthesia to facilitate tracheal intubation and to provide skeletal muscle relaxation during surgery.

제품 요약:

Package - Contents - Shelf Life: Vial, glass, - 10 dose units - 24 months from date of manufacture stored at or below 25°C 24 hours reconstituted stored at 15°C to 25°C (Controlled room temp)

승인 날짜:

1987-06-04

제품 특성 요약

Norcuron 200111 Version 2.0
Page 1
NEW ZEALAND DATA SHEET
NORCURON
Vecuronium bromide 4mg and 10mg injections
PRESENTATION
NORCURON contains as active substance vecuronium bromide. It is
supplied in a citrate-phosphate
buffered freeze-dried white to off-white dry cake or powder. No
preservative has been added.
NORCURON 4MG, POWDER FOR SOLUTION FOR INJECTION
Addition of 1mL water for injections results in a clear to almost
clear isotonic solution with pH 4
containing 4mg vecuronium bromide per mL (4mg/mL).
NORCURON 10MG, POWDER FOR SOLUTION FOR INJECTION
Addition of 5mL water for injections results in a clear to almost
clear isotonic solution with pH 4
containing 2mg vecuronium bromide per mL (2mg/mL)
USES
ACTIONS
Pharmacotherapeutic group: muscle relaxants, peripherally acting
agents, ATC code: M03A C03
NORCURON (vecuronium bromide) is a non-depolarising neuromuscular
blocking agent, chemically
designated as the aminosteroid 1-(3

, 17ß-diacetoxy-2ß piperidino-5

-androstan-16ß-yl)-1
methylpiperidinium bromide. NORCURON blocks the transmission process
between the motor nerve-
ending and striated muscle by binding competitively with acetylcholine
to the nicotinic receptors
located in the motor end-plate region of striated muscle.
Unlike depolarising neuromuscular blocking agents, such as
suxamethonium, NORCURON does not
cause muscle fasciculations.
Within the clinical dosage range, NORCURON exerts no vagolytic nor
ganglion blocking activity.
Tracheal intubation
Within 90 to 120 seconds following intravenous administration of a
dose of 0.08 to 0.10mg
vecuronium bromide per kg body weight, good to excellent conditions
for tracheal intubation occur
and within 3 to 4 minutes following administration of these dosages,
general muscle paralysis
adequate for any type of surgery is established.
The duration of action to 25% recovery of control twitch height
(clinical duration) with this dose is 24 to
60 minutes. The time to 95% recovery of control twitch height
following this dose is approximately 60
to 80 minutes